The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1453
October 13, 2014
View Complete Issue         Table of Contents 2019 
A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
October 13, 2014 (Issue: 1453)
The FDA has approved Cologuard (Exact Sciences), a stool DNA test, to screen average-risk adults ≥50 years old for colorectal cancer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
Article code: 1453c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.